newsfilter
← Earnings
Earnings Releases·

HCW Biologics — Third Quarter 2026 Earnings Summary

  • Q3 2026 revenue surged to $55.5 million from $15.6 million in the prior year period, while net loss narrowed to $3.2 million from $4.6 million; however, the nine-month revenue figure of $6.7 million remains significantly below the $27.2 million recorded in the same period of 2025.
  • The company faces substantial doubt regarding its ability to continue as a going concern for 12 months without additional funding, despite securing $8.6 million in equity financing and a debt facility of up to $10.0 million (with $3.0 million received at closing) during the nine-month period.
  • Strategic progress includes the activation of an additional clinical site for HCW9302, the initiation of cGMP manufacturing for HCW11-018b, and the closing of an exclusive worldwide licensing agreement for HCW11-006 with Beijing Trimmune Biotech.
  • Future outlook targets a Phase 1 readout and Recommended Phase 2 Dose determination for HCW9302 in Q1 2027, with an IND application for HCW11-018b in solid tumors expected in the first half of 2027.
Company
HCW BIOLOGICS INC
Sector
Healthcare
Industry
Biotechnology